We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarkers Correlated with Idiopathic Inflammatory Myopathy

By LabMedica International staff writers
Posted on 25 Sep 2018
Patients with idiopathic inflammatory myositis (IIM) typically present with muscle weakness, myalgia and in case of dermatomyositis (DM) also skin involvement. More...
Arthralgia is often present, but the articular manifestations are usually mild and non-destructive.

As rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs) are not routinely tested in idiopathic inflammatory myositis (IIM), little is known about their prevalence and clinical implications in this patient group. In anti-synthetase syndrome (ASS), presence of ACPA is reportedly associated with more severe and erosive arthritis.

Medical scientists at the University Hospitals Leuven (Leuven, Belgium) analyzed serum samples from 121 patients. Thirty diagnosed with polymyositis, 41 with dermatomyositis, 37 with ASS, five with necrotizing autoimmune myopathy or seven with overlap myositis and one with inclusion body myositis. RF was evaluated by nephelometry; anti-CCP antibodies were identified using fluoro enzyme immunoassays. Values above 40 IU/mL and 7 U/mL were considered positive for RF and ACPA, respectively.

The investigators observed no significant differences were observed between RF-positive and RF- negative IIM patients. The prevalence of RF and ACPA was 9.09% and 4.96%, respectively. The team observed a trend for RF-positive IIM patients to be older than RF-negative IIM patients and to more frequently carry ACPA antibodies and have lower forced expiratory volume in 1 second (FEV1) values (72% versus 88%). There was no statistically significant difference between patients who tested positive for both RF and ACPA, and patients who tested negative for both antibodies. The presence of RF or ACPA was not significantly associated with interstitial lung disease.

The authors concluded that their study demonstrated that RF and ACPA are prevalent in patients with IIM, but the detected prevalence is lower than the prevalence reported in previous studies in connective tissue diseases including IIM. Their results did not show a clear association between RF or ACPA positivity and specific clinical features or the occurrence of ILD or arthritis. The study was published originally published online on July 25, 2018, in the journal RMD Open.

Related Links:
University Hospitals Leuven


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.